Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Reldesemtiv

Generic Name: Reldesemtiv

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₈F_₂N_₆O

CAS Number: 1345410-31-2

Unique Ingredient Identifier: 4S0HBYW6QE

Overview

Reldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)).

Background

Reldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Phase 3

Terminated

Posted: 2022/07/05

Sponsor:Cytokinetics

ID:NCT05442775

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 3

Terminated

Posted: 2021/06/30

Sponsor:Cytokinetics

ID:NCT04944784

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Posted: 2017/05/19

Sponsor:Cytokinetics

ID:NCT03160898

A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

Phase 1

Terminated

Posted: 2017/02/28

Sponsor:Astellas Pharma Glob...

ID:NCT03065959

A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease

Phase 2

Completed

Posted: 2016/01/25

Sponsor:Astellas Pharma Glob...

ID:NCT02662582

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

New Drug Development Pipeline Shows Promise for ALS Treatment with 53 Candidates Under Investigation

2 years ago

A comprehensive review of ALS drug development reveals 53 new drug candidates in clinical trials between 2020-2022, with 13 compounds advancing to Phase 3 trials and showing promising therapeutic potential.

FDA Accepts Cytokinetics' NDA for Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction

3 years ago

The FDA has accepted Cytokinetics' New Drug Application (NDA) for omecamtiv mecarbil, a cardiac myosin activator, for treating heart failure with reduced ejection fraction (HFrEF).

Cytokinetics Unveils Vision 2025 and 2020 Corporate Milestones

5 years ago

Cytokinetics, Inc. has announced its Vision 2025, outlining key imperatives for the next five years, including achieving regulatory approvals for at least two drugs, building commercial capabilities, and expanding its development pipeline. The company also detailed its expected 2020 milestones, focusing on advancing cardiac and skeletal muscle programs, with significant clinical trial results anticipated.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy